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Glioblastoma is the most common and devastating type of malignant brain tumor.
We recently found that eribulin suppresses glioma growth in vitro and in vivo and
that eribulin is efficiently transferred into mouse brain tumors at a high concentra-
tion. Eribulin is a non-taxane microtubule inhibitor approved for breast cancer and
liposarcoma. Cells arrested in M-phase by chemotherapeutic agents such as micro-
tubule inhibitors are highly sensitive to radiation-induced DNA damage. Several
recent case reports have demonstrated the clinical benefits of eribulin combined
with radiation therapy for metastatic brain tumors. In this study, we investigated
the efficacy of a combined eribulin and radiation treatment on human glioblastoma
cells. The glioblastoma cell lines U87MG, U251MG and U118MG, and SJ28 cells, a
patient-derived sphere culture cell line, were used to determine the radiosensitizing
effect of eribulin using western blotting, flow cytometry and clonogenic assay. Sub-
cutaneous and intracerebral glioma xenografts were generated in mice to assess the
efficacy of the combined treatment. The combination of eribulin and radiation
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enhanced DNA damage in vitro. The clonogenic assay of U87MG demonstrated the
radiosensitizing effect of eribulin. The concomitant eribulin and radiation treatment
significantly prolonged the survival of mice harboring intracerebral glioma xenografts
compared with eribulin or radiation alone (P < .0001). In addition, maintenance
administration of eribulin after the concomitant treatment further controlled brain
tumor growth. Aberrant microvasculature was decreased in these tumors. Concomi-
tant treatment with eribulin and radiation followed by maintenance administration
of eribulin may serve as a novel therapeutic strategy for glioblastomas.
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1 | INTRODUCTION
Glioblastoma (GBM) is the most common malignant brain tumor and
one of the most devastating cancers in humans. Even with intensive
chemoradiotherapy after surgical resection, patients’ median overall
survival (OS) is <2 years.1 A series of large-scale genomic studies in
the last decade have provided a vast amount of information regard-
ing the genetic alterations in GBM, which may lead to a better
understanding of these tumors.2-4 It has, however, also been
revealed that the extensive molecular heterogeneity in GBM may be
responsible for the failure of a number of molecular targeting thera-
pies.5-7 A novel therapeutic strategy for GBM is desperately needed.
For a newly diagnosed GBM, a maximum safe surgical resection
followed by combined radiation therapy and chemotherapy with
temozolomide (TMZ) is the current standard of care. Radiation sup-
presses the growth of GBM and prolongs the survival of patients
with GBM, and, therefore, it is central to the treatment of GBM.8
Radiosensitization by arresting the cell cycle in M-phase has been
shown to increase the efficacy of radiation. A number of previous
reports have shown that cells arrested in M-phase by chemotherapy
are highly sensitive to DNA damage and that cell death is efficiently
induced in some cases, a phenomenon described as mitotic catastro-
phe.9-13
Eribulin methylate (eribulin), a non-taxane inhibitor of micro-
tubule dynamics, has been approved for late-stage and refractory
breast cancer, liposarcoma and sarcoma in many countries. The
mode of action is reported to be microtubule inhibition-dependent
apoptosis and normalization of the tumor microenvironment through
vascular remodeling.14-20 The distribution of eribulin to the normal
brain in mice has been reported to be low, and the clinical benefit of
this agent for GBM is considered to be limited.21,22 However,
recently, we found that eribulin penetrates brain tumor tissues at a
high concentration in an intracerebral mouse brain tumor model and
suppresses tumor growth, suggesting that eribulin may have activity
against GBM in a clinical setting (Takahashi, manuscript submitted).
In fact, consistent with its anti-microtubule activity, eribulin treat-
ment with radiation therapy has been shown to be effective against
brain metastasis from breast cancer in several case reports.23-26
Because radiation is a part of the standard therapy for newly diag-
nosed GBM, studying the effect of eribulin as a radiosensitizer has
great clinical value.
In this study, we investigated the effect and mechanism of a
combined eribulin and radiation treatment on suppressing glioma
growth in an intracerebral GBM xenograft model. We showed that
the combination induced DNA damage in vitro and prolonged sur-
vival in an intracranial xenograft mouse model. In addition, the con-
tinued administration of eribulin after radiation prevented tumor
recurrence and reduced abnormal angiogenesis. Our results suggest
that the concomitant administration of eribulin with radiation may
serve as an effective novel treatment strategy for GBM.
2 | MATERIALS AND METHODS
2.1 | Compound and cell lines
Eribulin (Halaven) was purchased from Eisai (Tsukuba, Japan). The
eribulin dose per administration for intracranial tumors was 0.5 mg/
kg, which is equivalent to the clinical dose in humans. For subcuta-
neous tumors, 0.05 or 0.5 mg/kg was used (see below). Injecting
these doses 3 times per week for a long period of time was found
to be safe and tolerable in a preliminary experiment even with whole
brain radiation therapy (data not shown). The human glioma cell lines
U87MG, U118MG and U251MG were provided by Professor Collins,
University of Cambridge, UK. All cell lines have been genotyped
(Takahashi, manuscript submitted). SJ28 cells, a stem-like glioma cell
line, were directly established from a surgical specimen of a glioblas-
toma patient at the National Cancer Center Hospital27 and serially
passaged under non-adherent culture conditions at 37°C/5% CO2 in
serum-free F12/DMEM supplemented with epidermal growth factor
and fibroblast growth factors.28
2.2 | Western blotting
Preparation of cell lysates, immunoblotting and immunoprecipitation
were performed as described previously.29 Membranes were
immunoblotted with antibodies against phospho-histone H3 (Cell
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Signaling; #9701, 1:2000), phospho-histone H2A.X (cH2AX, Milli-
pore; #05-636, 1:2000), caspase-3 (Cell Signaling; #9662, 1:1000),
Cleaved PARP (Asp214) (D64E10) XP (Cell Signaling; #5625,
1:2000), GAPDH (Cell Signaling; #2118S, 1:3000) or b-actin (Sigma;
A1978, 1:10 000). Signals were detected using a HRP-conjugated
secondary antibody (Cell Signaling; #7074S and #7076S, 1:3000) and
documented using an Amersham Imager 600 (GE Healthcare).
2.3 | Clonogenic assay
The clonogenic assay was performed as previously described with
some modifications.30 Briefly, cell lines were seeded in 25-cm2 flasks
with 5 mL of culture medium 20 hours before irradiation. Then, an
equal amount of eribulin or control solution was added to the cul-
ture flask 8 hours before irradiation. Cells were irradiated at 2, 4 or
6 Gy. Following irradiation, the cells were incubated at 37°C with
5% CO2. After 10-12 days, surviving colonies were fixed with 4%
buffered formalin solution (Muto Pure Chemical) and stained with
0.02% crystal violet solution (Sigma, C6158-50G). Colonies com-
posed of approximately 50 cells or more were counted. Cell survival
was calculated by dividing the number of cell colonies by the num-
ber of inoculated cells and plating efficiencies of the control cells in
each condition. The results were then calculated from the average of
3 independent experiments.
2.4 | Immunohistochemistry
Resected mouse brains were sliced and fixed in 10% buffered forma-
lin solution for 1 day and then embedded in paraffin. The presence
of a tumor was determined by H&E staining. For mean vascular area
(MVA) analysis, sections were incubated with goat anti-rat CD34
polyclonal antibody (R&D Systems; #AF4117, 1:100) and then with
the secondary antibody (anti-goat IgG- peroxidase; Sigma-Aldrich,
A5420, 1:200) and detected with the 3,3ʹ-diaminobenzidine sub-
strate (Sigma-Aldrich). Slides were counter-stained with hematoxylin.
Quantification of the CD34-positive vascular area was performed
using ImageJ software.31 MVA was calculated as the average of 5
vascular hot spots (500 9 500 lm2 in each spot) chosen in each
sample.
2.5 | Flow cytometry
Flow cytometry analysis was performed as previously described.30
Briefly, after eribulin (0.1, 1 and 10 nmol/L) exposure (12 and
24 hours), cells were harvested and fixed with 70% ethanol, treated
with RNase A, stained with propidium iodide (PI), and analyzed on a
FACSCalibur flow cytometer (Beckton Dickinson, Mountain View,
CA, USA).
2.6 | Quantification of cell death rate
The rate of cell death induction was assayed by co-staining of trea-
ted cells with propidium iodide (PI, Thermo Fisher Scientific) and
DAPI (Thermo Fisher Scientific). Fluorescence images of PI and DAPI
were acquired using an Olympus CKX53 microscope, and the num-
bers of PI-positive cells and DAPI-positive cells in each image were
obtained using ImageJ software (NIH). The rate of cell death was cal-
culated as (number of PI-positive cells)/(number of DAPI-positive
cells) 9 100 (%).
2.7 | Animals and tumor models
Glioma cell xenografts were generated as described previously.32
Briefly, U87MG cells (1 9 105 cells) for BALB/c-nu/nu female mice
(Charles River Laboratories Japan) or SJ28 cells (2.5 9 105 cells) for
SCID-Beige female mice (Charles River Laboratories Japan) were inocu-
lated into the right cerebral hemisphere with a Hamilton syringe and
stereotactic micro-injector (Narishige, Tokyo, Japan) in 2 lL of PBS. The
injection site coordinates were 1-mm anterior and 2-mm lateral to the
bregma and 3-mm deep from the dura mater. For the subcutaneous
model, U87MG cells (2 9 106 cells in 100 lL PBS) were injected sub-
cutaneously into the left leg of BALB/c-nu/nu male mice (Charles River
Laboratories Japan). The mice were subjected to irradiation (2-4 Gy)
restricted to the left leg or head while the rest of the body was pro-
tected by a lead shield. All treatments were performed when the mice
were 5-7 weeks old. Eribulin or saline was intraperitoneally injected.
The mouse weights and tumor sizes were measured at least twice a
week before starting treatment, and tumor volume was calculated using
the long axis and minor axis as described previously.33 All mice were
irradiated under anesthesia. All animal studies were approved by the
Animal Experimental Committee of the National Cancer Center and
were performed in accordance with the Guidelines for Animal Experi-
ments of the National Cancer Center, which concur with the ethical
guidelines for experimental animals in Japan.
2.8 | Irradiation
Cells were exposed to c-irradiation using a Gamma-Cell Exactor 40
(with 137-Cs) at approximately 1 Gy/min at the National Cancer
Center Research Institute in Japan. Mice were irradiated by X-rays
using a CP-160 (Acrobio) at approximately 0.33 Gy/min. Mice were
stabilized in irradiation containers during irradiation of the left leg.
The radiation dose for the mice was set to 4 Gy each time to simu-
late the clinical whole brain radiation dose of 2-4 Gy.34
2.9 | Statistics
Two-way ANOVA was performed for the in vitro clonogenic assay,
two-way RM ANOVA with Bonferroni post-tests were performed
for in vivo subcutaneous tumor data, and ANOVA with Bonferroni
post-tests were performed for the MVA analysis and abnormal mito-
tic cell count analysis for statistical comparisons between groups.
The Student t test was performed for cell death rate. P-values below
.05 were considered significant. A log-lank test was performed for
the Kaplan-Meier survival curve. All analyses were performed using
GraphPad Prism 5 software.
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3 | RESULTS
3.1 | Eribulin arrests the cell cycle of glioma cell
lines, induces DNA damage in mitotic phase when
combined with radiation, and shows a sensitizing
interaction in vitro
We first investigated the effect of eribulin on inhibiting microtubule
dynamics in the U87MG glioma cell line using flow cytometry. As
previously reported,18 we confirmed that eribulin induced cell cycle
arrest in G2/M-phase (Figure 1A). The phosphorylated form of his-
tone H3 was increased upon exposure to eribulin in a dose-depen-
dent manner with or without radiation (Figure 1B), suggesting that
M-phase arrest was induced by eribulin. Second, the efficacy of
the combination of irradiation and eribulin was assessed by examin-
ing the cell-cycle status and DNA damage in irradiated and/or
eribulin-treated U87MG cells. Upregulation of phosphorylated
H2AX (cH2AX) was evident 60 minutes after radiation was admin-
istered concomitantly with 1 or 10 nmol/L eribulin (Figure 1B).
Taken together, these data suggested that DNA damage may be
induced by irradiation in U87MG cells arrested at M-phase by
eribulin. We then assessed the death rate of U87MG and
U251MG cells upon exposure to eribulin and/or irradiation (Fig-
ure 1C). Increased cell death was induced by eribulin, and this was
significantly (P < .05, t test) enhanced by addition of radiation
(8 Gy). To investigate the mechanism of cell death, the caspase-
dependent apoptotic pathway was studied, as it is one of the best-
characterized mechanisms of programmed cell death. Cleaved cas-
pase-3 levels were increased upon exposure to 10 nmol/L eribulin
in all cell lines tested (Figure S1A). However, the enhancement of
this by the addition of radiation was not clearly demonstrated. We
further studied another apoptosis marker, cleaved PARP, to assess
the involvement of the caspase cascade in eribulin/irradiation-
induced cell death (Figure S1B). Cleaved PARP levels were signifi-
cantly increased when 0.5 nmol/L eribulin was combined with irra-
diation compared with irradiation or eribulin alone in U251MG
cells. However, the synergistic or additive effects of eribulin/irradia-
tion on caspase-dependent apoptosis were not clear at other doses
of eribulin in U251MG or at any doses in U87MG cells (Fig-
ure S1B). We further evaluated the involvement of the caspase
pathway in eribulin/irradiation-induced cell death (revised Fig-
ure 1C) by inhibiting caspase (Figure S1C). Death rates of neither
U87MG nor U251MG cells treated with a combination of eribulin
(5 nmol/L) and irradiation were reduced by addition of pan-caspase
inhibitor z-VAD-FMK (VAD), while cisplatin (CDDP)-induced cas-
pase-dependent cell death was significantly reduced (P < .01, t
test). Thus, the increased cell death caused by addition of radiation
to eribulin appeared to include a caspase-independent mechanism.
To further validate the radiosensitizing effect of eribulin, we per-
formed a clonogenic assay using U87MG cells. The adjusted killing
curve revealed a radio-sensitizing effect of eribulin (Figure S1D).
Taken together, these results suggested that the combination of
eribulin and radiation may be effective against GBM.
3.2 | Combined effects of eribulin and radiation
in vivo
The radiosensitizing effect of eribulin was then examined in vivo by
treating xenografted mice with either eribulin or radiation alone or
both in combination. For the intracerebral glioblastoma xenograft
model, 0.5 mg/kg eribulin per administration, which is equivalent to
the clinical dose for humans, was intraperitoneally administered 6
times in 12 days (Figure 2A). The local radiation dose was set to
3 9 4 Gy, and the body of the mice was protected from radiation.
For combined treatment, the xenografted tumors were irradiated
24 hours after eribulin injection, as was done in vitro. The results
showed that radiation alone did not have a survival benefit over the
untreated control, whereas 0.5 mg/kg eribulin significantly prolonged
the survival of mice harboring intracerebral U87MG xenografts (Fig-
ure 2B). When radiation and eribulin were concomitantly given,
however, radiation significantly prolonged the survival of mice with
intracerebral tumors compared to that in mice treated with either
radiation or eribulin alone. These data supported the idea that eribu-
lin has a radiosensitizing effect on mouse U87MG brain xenografts.
For the subcutaneous xenograft model, the radiosensitization
effect of eribulin was examined at a dose of 0.05 mg/kg given
3 times in 6 days instead of 0.5 mg/kg because 6 days of treatment
with 0.5 mg/kg eribulin alone was sufficient to completely suppress
the growth of subcutaneous tumors (Figure S2). The results showed
that eribulin (0.05 mg/kg) and radiation given concomitantly signifi-
cantly enhanced the growth suppression of the subcutaneous tumor
compared to that induced by either eribulin or radiation alone (Fig-
ure S3). To further clarify the growth-suppressive effects of eribulin,
radiation, and eribulin and radiation combined, we retrieved tissues
from the brains of mice harboring intracerebral xenografts treated
with each regimen and compared them morphologically using H&E-
stained sections (Figure 2C). In tumors treated with radiation alone,
although enlarged multi-nucleated cells and marked neutrophil inva-
sion with phagocyted dead cells were seen (Figure 2C, upper right,
arrow head), there was no difference in tumor volume compared to
that in untreated tumors. The histology of tumors treated with
eribulin alone revealed significantly (P < .05; one-way ANOVA Bon-
ferroni post-test) increased numbers of “abnormal mitotic cells,”35
suggesting that eribulin may have an inhibitory effect on microtubule
dynamics of tumor cells (Figure 2C, lower left, arrow, Figure S4).
Tumor tissues treated with the combination of eribulin and radiation
exhibited a markedly lower tumor volume and distinct cellular mor-
phology compared to those of tumors treated with radiation or
eribulin alone (Figure 2C, lower right). Cellular density was also low,
and many flattened and enlarged cells were observed. A similar sur-
vival benefit of the combined treatment was also confirmed in SJ28
cells, a patient-derived sphere culture cell line (Figure S5). In this
model, the radiation dose was reduced to 3 9 2 Gy because the
mouse strain used in this experiment (SCID/Beige) could not tolerate
3 9 4-Gy radiation (data not shown). These results strongly sug-
gested that the combined therapy of eribulin and irradiation had a
synergistic effect in in vivo brain tumor models.
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F IGURE 1 Effects of eribulin and irradiation on human glioma cell lines in vitro. A, The cell cycle status of U87MG cells was analyzed after
incubation with various doses of eribulin for 12 and 24 h by flow cytometry with propidium iodide staining. B, U87MG cells were treated with
eribulin at 3 different doses 24 h before irradiation and analyzed by western blotting in a time course up to 6 h. PTX; paclitaxel treatment at
100 nmol/L for 24 h. UV; 24 h after ultra-violet ray irradiation at 254 nm. C, The indicated glioblastoma cell lines were seeded on collagen-
coated culture dishes. After 16 h, the cells were treated with the indicated dose of eribulin followed by irradiation (8 Gy). The cells were
further cultured for 72 h, and induction of cell death was quantified as described in the Materials and Methods section. Data shown are mean
values  SD from 3 independent experiments
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3.3 | Survival benefits of the maintenance
administration of eribulin after the combined therapy
We further determined whether the continued administration of
eribulin produced a more sustained effect on the inhibition of micro-
tubule dynamics and suppression of tumor growth. To validate this
hypothesis, we performed another set of experiments using U87MG
brain xenografted mice (Figure 3). In one set of animals (n = 6),
eribulin (0.5 mg/kg) was given intraperitoneally 3 times/week contin-
ually until the mice had deteriorated and were euthanized. In
another set (n = 7), 4 Gy radiation was given 3 times in the first
week alone, and eribulin (0.5 mg/kg, 3 times/week) was given con-
tinually until the mice had deteriorated (Figure 4). The survival rates
of the mice continually treated with eribulin with or without radia-
tion were compared with those of untreated U87MG brain xeno-
grafted mice (n = 3) or those treated with radiation alone (n = 3).
The results showed that while the animals continually treated with
eribulin alone survived significantly longer than the untreated con-
trols or those treated with radiation alone, those treated with
radiation and continual eribulin lived significantly longer than those
treated with eribulin alone; only 2 mice died as a result of the brain
tumor 80 days after the initiation of the treatment (Figure 3B).
These results further confirmed the synergistic effect of eribulin and
radiation, which suggests that the cytostatic effect of the long-term
administration of 0.5 mg/kg eribulin after concomitant therapy with
radiation may lead to sustained tumor control.
3.4 | Effects of eribulin on tumor vascular area
after radiation in intracranial xenograft models
It is widely known that abnormal angiogenesis occurs after tumor
irradiation and that it may contribute to tumor recurrence.36,37 Since
the suppressive effect of eribulin on vascular remodeling was
recently reported,19,20 we determined whether eribulin administra-
tion neutralized the radiation-induced abnormal vascularization in
tumors. The treatment schedule was optimized to evaluate vascular
remodeling,20 especially to assess the late effects of radiation (Fig-
ure 4A). Figure 4B presents representative histopathological images.
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F IGURE 2 Effects of eribulin and
irradiation on intracranial U87MG cell
xenograft mouse models. A,
Scheme showing the treatment schedules
of the 4 regimens: Control, saline injection,
and no radiation therapy; Radiation, saline
injection, and irradiation (4 Gy 93);
Eribulin, eribulin (0.5 mg/kg) injection, and
no radiation therapy; and
Eribulin + Radiation, eribulin (0.5 mg/kg)
injection, and irradiation (4 Gy 93). B, A
Kaplan-Meier survival curve of mice
harboring U87MG intracerebral xenografts
treated with eribulin and radiation. There
were 9-10 mice in each group. C,
Representative H&E-stained histological
images of U87MG xenografts at the end of
the treatment schedule
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Although the difference was not statistically significant, the irradi-
ated xenografts tended to have a higher MVA compared to that of
the control group. When eribulin was given concomitantly with or
after irradiation, however, MVA was significantly higher in the eribu-
lin +/after irradiated group compared with that in the radiation alone
group (Figure 4C). These results suggested that eribulin may normal-
ize the radiation-induced aberrant vascular microenvironment.
4 | DISCUSSION
In the present study, we demonstrated that eribulin exerted a syner-
gistic effect with radiation to suppress the growth of glioma cells
(Figure 1). Moreover, the concomitant eribulin and radiation treat-
ment significantly prolonged the survival of mice with intracerebral
xenografts of gliomas compared to that of mice treated with eribulin
or radiation monotherapy (Figure 2). We previously showed that
intravenously administered eribulin reached xenografted mouse brain
tumor tissues at a high concentration comparable to that in plasma,
and that a clinically equivalent dose of eribulin significantly pro-
longed survival of mice intracerebrally xenografted with U87MG or
several other patient-derived serum-free cultured glioma cells (Taka-
hashi, manuscript submitted). Together with these data, our results
strongly suggest that the combined eribulin and radiation treatment
may serve as an attractive, novel therapeutic strategy for newly
diagnosed GBM. The potential mechanisms by which eribulin and
radiation cooperate to suppress glioma growth are discussed below
(Figure 5).
First, we demonstrated that DNA damage was induced by the
combined eribulin and radiation treatment. It is plausible that radia-
tion-induced DNA damage was enhanced by cell cycle arrest, most
likely at M-phase, by eribulin. We showed that the combination of
eribulin and radiation increased cell death in glioma cells through a
caspase-independent mechanism. We further validated the radiosen-
sitizing effect of eribulin. The combined eribulin and radiation treat-
ment showed increased DNA damage and death rates in U87MG
cells, suggesting the synergistic effect of the combined treatment
(Figure S1D). It should be noted that the dosage of eribulin was
reduced to 0.05 nmol/L in this assay, which was below the level at
which eribulin induced cell cycle arrest, because eribulin itself has a
strong colony formation-inhibiting activity in glioma cell lines. We
hypothesize that the mechanism for this effect may be at least in
part due to inhibition of microtubule dynamics, which may enhance
the cytocidal effect of radiation. In the in vivo experiments, eribulin
alone significantly increased the number of “abnormal mitotic cells,”
suggesting that eribulin may have an inhibitory effect on microtubule
dynamics (Figure 2C, Figure S4). The fact that these cells were not
seen in the tumor tissues treated with the combination of eribulin
and radiation therapy suggests the possibility that they were mostly
eradicated by irradiation because of their enhanced radiation sensi-
tivity conferred by eribulin. Although determination of the exact
mechanisms of cell death induced by the combination of eribulin and
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F IGURE 3 Effects of the maintenance administration of eribulin after concomitant administration of irradiation in intracranial U87MG
xenograft mouse models. A, Scheme showing the treatment schedules of the 4 regimens: (i) 3 times/wk continual saline injection and no
irradiation; (ii) 3 times/wk continual saline injection and irradiation (4 Gy 93); (iii) 3 times/wk continual eribulin (0.5 mg/kg) injection and no
irradiation; and (iv) 3 times/wk continual eribulin (0.5 mg/kg) injection and irradiation (4 Gy 93). B, A Kaplan-Meier curve of mice harboring
U87MG intracranial xenografts treated with the concomitant administration of eribulin and irradiation followed by continual (maintenance)
administration of eribulin. There were 3 mice in the control and irradiated groups, 6 mice in the eribulin-treated group and 7 mice in the
combination treatment group
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irradiation is beyond the scope of this study, it warrants further
investigation.
Another mechanism for the effect of the combined eribulin and
radiation treatment on synergistically suppressing tumor growth may
be vascular remodeling conferred by eribulin. There have been sev-
eral reports that demonstrate vascular normalization effects of eribu-
lin on tumor microvasculature. In a preclinical human breast cancer
model, Funahashi et al20 showed that eribulin induced the remodel-
ing of the vasculature in xenografted tumors and improved perfusion
in the tumor tissues, particularly in the tumor core. Ueda et al19
examined breast cancer patients treated with eribulin using in vivo
imaging and found that oxygen saturation in the tumor was signifi-
cantly increased. Hypoxia is a well-known source of resistance to
radiation and chemotherapy.36 These findings suggest that eribulin
may enhance the effect of radiation by re-oxygenating tumor tissues
through vascular remodeling. In our study, a combination of eribulin
and radiation treatment, whether eribulin was given before or after
radiation, significantly reduced the mean vascular areas of
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F IGURE 4 Effects of eribulin on the microvasculature in intracranial U87MG xenograft mouse models. The irradiation dose was increased
to 8 Gy to observe its effect on the microvasculature. A, Scheme showing the treatment schedules of the regimen: (i) Saline injection and no
irradiation; (ii) saline injection and single fraction of 8 Gy irradiation only; (iii) eribulin (0.5 mg/kg) injection and no irradiation; (iv) eribulin
(0.5 mg/kg) injection and a single fraction of 8 Gy irradiation; and (v) eribulin (0.5 mg/kg) injection only after irradiation. The control group
contained 4 mice, and the other groups contained 3 mice. All mice were euthanized on day 16. B, Representative histological images of
immunohistochemical staining with CD34, an endothelial marker, and counterstaining with hematoxylin are shown. C, A quantitative analysis of
the mean vascular area. Data are shown as the mean  SD. n.s., not significant
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xenografted brain tumor tissues compared with radiation treatment
alone (Figure 4C). Treatment by eribulin alone also showed the ten-
dency to reduce the mean vascular area in tumors as compared to
untreated controls, although the difference did not reach statistical
significance. Although our data are limited, these results support the
notion that eribulin normalizes tumor microvasculature.
On the other hand, radiation itself also induces hypoxia.36-38
Lesions in a tumor where abnormal blood vessels develop may be
susceptible to hypoxia because of the unstable blood flow (“cycling
hypoxia lesion”), possibly activating HIF-1.37 Radiation could cause
the lesion to become reoxygenated as a consequence of effective
oxygenated tumor cell death. However, this may also generate reac-
tive oxygen species (ROS) in the oxygenated lesion and stabilize
HIF-1, eventually further enhancing angiogenesis to support tumor
growth.36 We showed that the combination of eribulin and radiation
resulted in a significant decrease in MVA in xenografted mouse brain
tumor tissues (Figure 4). A decrease in MVA has been associated
with vascular remodeling in the tumor, which could lead to improved
perfusion, oxygenation and drug delivery.19,20 Thus, we consider that
the vascular remodeling induced by eribulin may suppress radiation-
induced angiogenesis and play a crucial role in the efficacy of the
combined radiation and eribulin therapy by normalizing the microen-
vironment and inducing re-oxygenation. To confirm this hypothesis,
further studies exploring hypoxic status in the tumor microenviron-
ment are warranted.
It has also been reported that in breast cancer patients, beva-
cizumab non-responders showed higher degrees of angiogenesis
with more severe hypoxia during bevacizumab treatment compared
to responders.39 Oxygen saturation in breast cancers was shown to
increase in patients treated with eribulin but not in those treated
with bevacizumab.19 These data suggest that eribulin may also be
beneficial to patients with GBM who do not respond to beva-
cizumab.
Another intriguing finding is that the continual administration of
eribulin after concomitant treatment with eribulin and radiation
resulted in a more sustained inhibition of tumor growth in intracere-
bral U87MG xenografts than eribulin alone (Figure 3B). It was partic-
ularly notable that only a single cycle (4 Gy 93) of irradiation given
in the first week, which did not improve the survival of the brain
tumor-bearing mice on its own, was sufficient to significantly
enhance the life-prolonging effect of eribulin (Figure 2B). It is possi-
ble that the initial concomitant eribulin and radiation treatment was
so effective at killing glioma cells that the maintenance administra-
tion of eribulin more efficiently controlled recurrence than eribulin
alone. The mechanism of the prolonged cytostatic effect of mainte-
nance eribulin when combined with radiation requires further inves-
tigation.
Taken together, we propose a new therapeutic strategy for
GBM: a concomitant treatment with eribulin and radiation to
radiosensitize tumor cells followed by a maintenance administration
of eribulin. The concomitant treatment with eribulin radiosensitizes
tumor cells to maximize the effect of radiation and rectify the
hypoxia and abnormal angiogenesis induced by radiation. The main-
tenance eribulin treatment has an enhanced cytostatic effect on the
remaining/surviving tumor cells (Figure 5). One limitation of our
study is that we focused on the U87MG glioma cell line for the
in vivo experiments, because it was a well-established brain tumor
model. Biological behavior of gliomas is diverse, however, so it is
possible that the response of other glioma cells to the concomitant
eribulin and radiation treatment may be different. Nonetheless, we
have previously confirmed that eribulin significantly prolonged sur-
vival of intracerebral xenografts of several patient-derived glioma
cells (Takahashi, submitted). We therefore consider that the com-
bined eribulin and radiation treatment would be effective in a wide
range of gliomas. It is hoped that the new strategy will be effective
even for GBM cases that are resistant to TMZ or bevacizumab. A
clinical trial to test the efficacy of the combined treatment is war-
ranted.
In summary, we showed that eribulin when combined with
radiation efficiently suppressed the growth of engrafted mouse
brain tumors, possibly through: (i) a radiosensitizing effect, possi-
bly by either inducing M-phase arrest and/or an inhibitory effect
on microtubule dynamics: (ii) the normalization of abnormal
angiogenesis and reoxygenation of the microenvironment, which
would lead to better radiosensitivity and local drug delivery; and
(iii) a sustained cytostatic effect of the maintenance administra-
tion. Our ultimate aim is to establish a novel effective therapeu-
tic strategy for newly diagnosed GBM. The concomitant eribulin
and radiation treatment hopefully represents a step towards this
goal.
Eribulin with radiation therapy
Radiation Therapy 
Reoxygenation
Improve combination drug delivery
Inhibit abnormal angiogenesis
Prevent recurrence
Concomitant
administrationPre-administration Post-administration
Radiosensitizing effect
F IGURE 5 Treatment strategy of
eribulin administration combined with
irradiation at 3 different phases: (i) pre-
administration of eribulin reoxygenates the
tumor core, increases the effect of
radiation and increases drug delivery; (ii)
concomitant administration of eribulin has
a radiosensitizing effect; and (iii)
maintenance administration of eribulin
after radiation decreases the abnormal
vascularization of irradiated tumors and
may lead to sustained tumor control
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